Skip to content

Remote Ischemic Preconditioning With Postconditioning in Heart Transplantation Surgery

Cardioprotective Effects of Remote Ischemic Preconditioning With Postconditioning of the Recipient on Donor Heart in Heart Transplantation Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02149316
Enrollment
60
Registered
2014-05-29
Start date
2014-02-28
Completion date
2016-02-29
Last updated
2016-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy, End Stage Heart Disease, Heart Failure, Myocardial Ischemic Reperfusion Injury

Brief summary

The purpose of this study is to determine whether remote ischemic preconditioning with postconditioning (RIPC+RIPostC) reduces myocardial injury and improves clinical outcomes in heart transplantation surgery.

Interventions

PROCEDURERIPC+RIPostC

Four 5 min cycles of upper limb ischemia and reperfusion by a cuff inflated to 200 mmHg, twice (after anesthesia induction and before surgery started, at 20min after aortic declamping)

PROCEDUREcontrol

a deflated cuff placed on the right upper arm

Sponsors

Chinese Academy of Medical Sciences, Fuwai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
14 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* scheduled for elective orthotopic heart transplantation surgery

Exclusion criteria

* peripheral vascular disease affecting the upper arms * mechanical circulatory support before surgery * taking the antidiabetic sulphonylurea, glibenclamide * cold ischemic time of donor heart \> 12 hours * repeated heart surgery

Design outcomes

Primary

MeasureTime frame
serum cardiac troponin I (cTnI)within 72 hours after aortic declamping

Secondary

MeasureTime frame
plasma microRNA-133b (miR-133b)within 72 hours after aortic declamping
plasma microRNA-208a (miR-208a)within 72 hours after aortic declamping

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026